Bristol Myers Squibb

HIRING · 1 OPEN AI

About

Apply, adapt, and in some cases create multi-modal foundation models such as large language models (LLMs), diffusion models, and encoder architectures to answer biological domain-specific questions
Address real-world biological modeling challenges such as data sparsity, class imbalance, noise, experimental bias, and heterogeneity of effects
Thoughtful model evaluation that incorporates appropriate benchmarks, statistical tests, and problem understanding to support technical and business dec...

Bristol Myers Squibb

About

Updates & Highlights

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

Bristol Myers Squibb (BMY) Unveils Five Year Camzyos Data At ESC Congress

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors

Recent Openings

Senior Specialist, PDS BI&T - AI Engineering & Enablement

All Jobs

Senior Specialist, PDS BI&T - AI Engineering & Enablement

Culture & Mission

Benefits & Perks

Competitive Salary

Equity/Stock Options

Health Insurance

Remote Work

Learning Budget

Generous PTO

Parental Leave

401(k) Match

Tech Stack

Core Values

Innovation

Collaboration

Excellence

Impact

Office Locations

Team

Are you on the team at Bristol Myers Squibb?

News & Press

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

Bristol Myers Squibb (BMY) Unveils Five Year Camzyos Data At ESC Congress

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors

Bristol Myers Squibb (BMY) Stock Looks Reasonable On Earnings Yet Strong Returns Test Value

Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb

Bristol Myers Squibb Invests $173 Million to Expand U.S. Radiopharmaceutical Manufacturing

Bristol Myers Squibb (BMY) After ZENBEXUS Approval Faces A Fully Valued Debate

Glenview Trust Co Invests $5.89 Million in Bristol Myers Squibb Company $BMY

Coastal Bridge Advisors LLC Takes $3.27 Million Position in Bristol Myers Squibb Company $BMY

Bristol Myers Squibb exits Cellares pact (update) (BMY:NYSE)

Bristol Myers Squibb (BMY) Faces New Patent Challenge Over Heart Drug Rights

What Does Bristol Myers Squibb (BMY) Face After ZENBEXUS Approval And Patent Action?

Legal & General Group Plc Purchases Shares of 17,022,940 Bristol Myers Squibb Company $BMY

Chai Discovery Partners with Bristol Myers Squibb for AI-Driven Antibody Discovery

What Could Bristol Myers Squibb (BMY) AI Antibody Deal Mean For Drug Discovery?

Chai tees up Bristol Myers Squibb AI antibody discovery collab

Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Stock Fully Priced?

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

Bristol Myers Squibb picks Houston for multi-modality $2.3bn manufacturing campus